|本期目录/Table of Contents|

[1]徐建军,刘殿明.雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效比较[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):38-39，60.[doi:10.3969/j.issn.1672-271X.2015.01.012]
　XU Jian-jun,LIU Dian-ming..Raltitrexed intraperitoneal/intravenous route of administration， the efficacy of the treatment of colorectal cancer ascites comparison[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(01):38-39，60.[doi:10.3969/j.issn.1672-271X.2015.01.012]
点击复制

雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效比较()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年01期
页码:
38-39，60
栏目:
出版日期:
2015-01-31

文章信息/Info

Title:
Raltitrexed intraperitoneal/intravenous route of administration， the efficacy of the treatment of colorectal cancer ascites comparison
作者:
徐建军; 刘殿明
200052 上海，解放军455医院普外科
Author(s):
XU Jian-jun;  LIU Dian-ming.
Department of General Surgery， 455 Hospital of PLA， Shanghai 200052， China
关键词:
结直肠肿瘤; 药物疗法; 雷替曲塞
Keywords:
colorectal cancer;  drug therapy;  raltitrexed
分类号:
R735.34
DOI:
10.3969/j.issn.1672-271X.2015.01.012
文献标志码:
A
摘要:
目的 探讨雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效。方法 经病理或细胞学确诊的50例晚期结直肠癌腹水患者分为观察组(n=25)和对照组(n=25)。观察组方案:雷替曲塞3 mg/m2腹腔灌注，奥沙利铂120 mg/m2静滴。对照组方案:雷替曲塞3 mg/m2静滴，奥沙利铂120 mg/m2静滴。两方案均3周为1周期，每周期评价不良反应，每3个周期评价疗效，直至疾病进展或毒性不能耐受，最多治疗12个周期，比较两组的有效率(RR)、疾病控制率(DCR)、中位肿瘤进展时间(mTTP)及不良反应发生率。结果 两组RR分别为20%和8%(P<0.05)，DCR分别为92%和84%(P＞0.05)及mTTP分别为4.5个月和3.6个月(P<0.05)。观察组1、2级丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)升高发生率为4%，对照组为24%(P＜0.05)；对照组1、2级中性粒细胞减少、口腔黏膜炎的发生率(分别为48%与32%)，均高于观察组(20%与8%)(P＜0.05)。结论 雷替曲塞腹腔给药疗效优于静脉给药，不良反应更轻，可以作为结直肠癌晚期腹水的有效姑息治疗方案。
Abstract:
Objective To investigate the effect in peritoneal/intravenous route of administration for the treatment of colorectal cancer ascites by raltitrexed. Methods There were histologically or cytologically diagnosed 50 cases of advanced colorectal cancer patients with ascites， which were divided into the trial group (n=25) and the control group (n=25). The trial group: raltitrexed 3 mg/m2 intraperitoneal perfusion， oxaliplatin intravenous infusion of 120 mg/m2， the first day. The control group: raltitrexed intravenous infusion of 3 mg/m2. Oxaliplatin intravenous infusion of 120 mg/m2， the first day. The two group were 3 weeks for 1 cycles， and toxicity and curative effect were evaluated every cycle and every 3 cycles until disease progression or intolerant toxicity. The maximum was 12 cycles of treatment. To compared response rate (RR)， disease control rate (DCR)， the median progression (mTTP) and adverse effects rate of two groups. Results RR of two groups was 20% and 8% (P<0.05)， DCR was 92% and 84% (P>0.05) and mTTP was 4.5 months and 3.6 months (P<0.05). 1， 2 level incidence of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) of the trial group was 4%， lower than 24% of the control group (P<0.05)； 1， 2 level neutropenia and mucositis incidence rates of the control group were 48% and 32%，the rates of the trial group were 20% and 8%，the rates of the control group were higher than that of the trial group (P<0.05). Conclusion The effect of raltitrexed celiac injection was better than intravenous administration， and toxicity was lighter， so it can be used as an effective palliative treatment options for metastatic colorectal cancer in advanced ascites.

参考文献/References:

［1］梁 冲，王跃华，李增才，等.氟尿嘧啶缓释剂在老年结肠癌术后疗效的观察［J］．东南国防医药，2010，12(4):299-301.
［2］王佳蕾，李 进，秦叔逵，等.雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验［J］．临床肿瘤学杂志，2012，17 (1):6-11.
［3］Liu Y，Wu W，Hong W，et al.Raltitrexed-based chemotherapy for advanced colorectal cancer［J］．Clin Res Hepatol Gastroenterol，2014，38(2):219-225.
［4］陈 洁，谢国群，贺天临，等.以雷替曲塞为主双途径化疗治疗晚期大肠癌的临床研究［J］．中国老年保健医学，2013，11(3):40-42.
［5］Khouri C，Guiu B，Cercueil JP，et al.Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer:a retrospective study［J］．Anticancer Drugs，2010，21(6):656-661.
［6］覃金莲，陆永奎，刘 莎，等.雷替曲塞对比5-氟尿嘧啶一线治疗晚期结直肠癌疗效和不良反应的Meta分析［J］．中国现代医学杂志，2013，23(14):84-90.
［7］杨学宁，吴一龙.实体瘤治疗疗效评价标准——RECIST［J］．循证医学，2004，4(2):85-90.
［8］CTCAEv 4.0，Common Terminology Criteria for Adverse Events［EB/OL］.
［2011/09/01］ http://www.calgb.org/Public/meetings/presentations/2009/summer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf.
［9］Ransom D，Wilson K，Fournier M，et al.Final results of Austral asian gastrointestinal trials group ARCTIC study:an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrim idines［J］．Ann Oncol，2014，25(1):117-121.
［10］甘建琛.结直肠癌的腹腔化疗［J］．医学综述，2006，12(4):214-217.
［11］Claire K，Neel B，Mark H，et al.Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history［J］．Eur J Cancer，2013，49(10):2303-2310.
［12］Jacquet P，Averbach AM，Stephens AD，et al.Cancer recurrencefollowing laparoscopiccolectomy.Report of two patients treated with heated intraperitoneal chemotherapy［J］．Dis Colon Rectum，1995，38(10):1110-1114.
［13］池 畔，林惠铭，林舜国，等.大肠癌术后行不同腹腔化疗方案的疗效及并发症比较［J］．中华普通外科杂志，2000，15(7):402-404.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2015-01-20